4-(5-(phenanthren-2-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)aniline | 882854-64-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 菲及其衍生物
• 英文名称: 4-(5-(phenanthren-2-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)aniline
• 英文别名: 4-(5-phenanthren-2-yl-3-trifluoromethyl-pyrazol-1-yl)-phenylamine；4-[5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrozol-1-yl]phenylamine；4-(5-Phenanthren-2-yl-3-trifluoromethyl-pyrazol-1-yl)-phenylamine；4-[5-phenanthren-2-yl-3-(trifluoromethyl)pyrazol-1-yl]aniline
• CAS: 882854-64-0
• 化学式: C₂₄H₁₆F₃N₃
• 分子量: 403.406
• InChiKey: IENKCMPNLOLSCO-UHFFFAOYSA-N

物化性质

• 沸点：
  589.5±50.0 °C(Predicted)
• 密度：
  1.33±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  6.3
• 重原子数：
  30
• 可旋转键数：
  2
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.04
• 拓扑面积：
  43.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  4-(5-(phenanthren-2-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)aniline 在 盐酸 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 四氢呋喃 、 乙酸乙酯 为溶剂， 生成 (2R)-2,6-diamino-N-[4-[5-phenanthren-2-yl-3-(trifluoromethyl)pyrazol-1-yl]phenyl]hexanamide
  参考文献：
  名称：

  Development of novel antibacterial agents against methicillin-resistant Staphylococcus aureus

  摘要：

  Methicillin-resistant Staphylococcus aureus (MRSA) poses a serious threat to public health because of its resistance to multiple antibiotics most commonly used to treat infection. In this study, we report the unique ability of the cyclooxygenase-2 (COX-2) inhibitor celecoxib to kill Staphylococcus aureus and MRSA with modest potency. We hypothesize that the anti-Staphylococcus activity of celecoxib could be pharmacologically exploited to develop novel anti-MRSA agents with a distinct mechanism. Examination of an in-house, celecoxib-based focused compound library in conjunction with structural modifications led to the identification of compound 46 as the lead agent with high antibacterial potency against a panel of Staphylococcus pathogens and different strains of MRSA. Moreover, this killing effect is bacteria-specific, as human cancer cells are resistant to 46. In addition, a single intraperitoneal administration of compound 46 at 30 mg/kg improved the survival of MRSA-infected C57BL/6 mice. In light of its high potency in eradicating MRSA in vitro and its in vivo activity, compound 46 and its analogues warrant continued preclinical development as a potential therapeutic intervention against MRSA. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.06.018
• 作为产物：
  描述：

  4,4,4-三氟-1-(2-菲基)-1,3-丁烷二酮 在 盐酸 、 platinum(IV) oxide 、 氢气 作用下， 以 乙醇 为溶剂， 生成 4-(5-(phenanthren-2-yl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)aniline
  参考文献：
  名称：

  Development of novel antibacterial agents against methicillin-resistant Staphylococcus aureus

  摘要：

  Methicillin-resistant Staphylococcus aureus (MRSA) poses a serious threat to public health because of its resistance to multiple antibiotics most commonly used to treat infection. In this study, we report the unique ability of the cyclooxygenase-2 (COX-2) inhibitor celecoxib to kill Staphylococcus aureus and MRSA with modest potency. We hypothesize that the anti-Staphylococcus activity of celecoxib could be pharmacologically exploited to develop novel anti-MRSA agents with a distinct mechanism. Examination of an in-house, celecoxib-based focused compound library in conjunction with structural modifications led to the identification of compound 46 as the lead agent with high antibacterial potency against a panel of Staphylococcus pathogens and different strains of MRSA. Moreover, this killing effect is bacteria-specific, as human cancer cells are resistant to 46. In addition, a single intraperitoneal administration of compound 46 at 30 mg/kg improved the survival of MRSA-infected C57BL/6 mice. In light of its high potency in eradicating MRSA in vitro and its in vivo activity, compound 46 and its analogues warrant continued preclinical development as a potential therapeutic intervention against MRSA. (C) 2012 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2012.06.018

文献信息

• [EN] PDK-1/AKT SIGNALING INHIBITORS<br/>[FR] INHIBITEURS DE SIGNALISATION PDK-1/AKT
  申请人：UNIV OHIO STATE RES FOUND

  公开号：WO2005044130A1

  公开（公告）日：2005-05-19

  A new class of phosphoinositide-dependent kinase-1 (PDK-1) inhibitors of formula (I): wherein X is selected from the group consisting of alkyl and haloalkyl; Ar is an aryl radical selected from the group consisting of phenyl, biphenyl, naphthyl, anthryl, phenanthryl, and fluorenyl; and wherein Ar is optionally substituted with one or more radicals selected from the group consisting of halo, C1 C4 alkyl, C1 C4 haloalkyl, azido, C1 C4 azidoalkyl, aryl, akylaryl, haloaryl, haloalkylaryl, and combinations thereof; and R is selected from the group consisting of nitrile, acetonitrile, ethylnitrile, propylnitrile, carboxamide, amidine, tetrazole, oxime, hydrazone, acetamidine, aminoacetamide, guanidine, and urea. Also provided are methods of using the compounds for the treatment and prevention of cancer in humans.

  一种新的磷脂酰肌醇依赖性激酶-1（PDK-1）抑制剂的化学式（I）：其中X选自烷基和卤代烷基组成的群体；Ar是从苯基、联苯基、萘基、蒽基、菲基组成的基团中选取的芳基基团；其中Ar可选择地被一个或多个从卤素、C1-C4烷基、C1-C4卤代烷基、叠氮化物、C1-C4叠氮基烷基、芳基、烷基芳基、卤代芳基、卤代烷基芳基等组成的基团取代；R选自腈、乙腈、乙腈、丙腈、羧酰胺、胺基、四唑、肟、醛肟、乙酰胺、氨基乙酰胺、胍、尿素等组成的群体。还提供了使用这些化合物用于人类癌症的治疗和预防的方法。
• ANTI-INFECTIVE AGENTS AGAINST INTRACELLULAR PATHOGENS
  申请人：Chen Ching-Shih

  公开号：US20090111799A1

  公开（公告）日：2009-04-30

  A new class of phosphoinositide-dependent kinase-1 (PDK-1) inhibitors of Formula I: wherein X wherein X is —CF 3 , Ar is selected from and R is selected from where R′ is L-Lys, D-Lys, β-Ala, L-Lue, L-Ile, Phe, SO 2 CH 2 CH 2 NH 2 , SO 2 NH 2 , Asn, Glu or Gyl, and R″ is methyl, ethyl, allyl, CH 2 CH 2 OH, CH 2 CN, CH 2 CH 2 CN, CH 2 CONH 2 ,

  一种新的磷脂酰肌醇依赖激酶-1（PDK-1）抑制剂的化学式I：其中X为—CF3，Ar从中选择，R从中选择，其中R′为L-赖氨酸，D-赖氨酸，β-丙氨酸，L-亮氨酸，L-异亮氨酸，苯丙氨酸，SO2CH2CH2NH2，SO2NH2，天冬氨酸，谷氨酸或甘氨酸，R″为甲基，乙基，烯丙基，CH2CH2OH，CH2CN，CH2CH2CN，CH2CONH2。
• PDK-1/Akt signaling inhibitors
  申请人：Chen Ching-Shih

  公开号：US20060079566A1

  公开（公告）日：2006-04-13

  A new class of phosphoinositide-dependent kinase-1 (PDK-1) inhibitors of formula I: wherein X is selected from the group consisting of alkyl and haloalkyl; Ar is an aryl radical selected from the group consisting of phenyl, biphenyl, naphthyl, anthryl, phenanthryl, and fluorenyl; and wherein Ar is optionally substituted with one or more radicals selected from the group consisting of halo, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, azido, C 1 -C 4 azidoalkyl, aryl, akylaryl, haloaryl, haloalkylaryl, and combinations thereof; and R is selected from the group consisting of nitrile, acetonitrile, ethylnitrile, propylnitrile, carboxamide, amidine, tetrazole, oxime, hydrazone, acetamidine, aminoacetamide, guanidine, and urea. Also provided are methods of using the compounds for the treatment and prevention of cancer in humans.

  一种新的磷脂酰肌醇依赖性激酶-1（PDK-1）抑制剂，化学式为I：其中X选自烷基和卤代烷基；Ar是选自苯基，联苯基，萘基，蒽基，菲基和芴基的芳基基团；其中Ar可选地被一个或多个选自卤素，C1-C4烷基，C1-C4卤代烷基，叠氮基，C1-C4叠氮烷基，芳基，烷基芳基，卤代芳基，卤代烷基芳基和其组合的基团取代；而R选自腈，乙腈，丙腈，羧酰胺，胍，四唑，肟，腙，乙酰胍，氨基乙酰胺，胍，尿素等基团。还提供了使用该化合物治疗和预防人类癌症的方法。
• Anti-staphylococcal celecoxib derivatives
  申请人：Chen Ching-Shih

  公开号：US09079899B2

  公开（公告）日：2015-07-14

  A method of treating infection by Staphylococcus in a subject by administering a pharmaceutical composition including a celecoxib derivative of formula I or a pharmaceutically acceptable salt thereof is described. The preparation of numerous celecoxib derivatives for testing as potential anti-staphylococcal agents is also described.

  本文描述了一种通过给予含有公式I的Celecoxib衍生物或其药学上可接受的盐的药物组合物来治疗受金黄色葡萄球菌感染的受体的方法。同时，本文也描述了制备多种Celecoxib衍生物以测试其作为潜在抗金黄色葡萄球菌药物的能力。
• PDK-1/AKT SIGNALING INHIBITORS
  申请人：Chen Ching-Shih

  公开号：US20110015242A1

  公开（公告）日：2011-01-20

  Use of a new class of phosphoinositide-dependent kinase-1 (PDK-1) inhibitors of formula I for inducing apoptosis in unwanted rapidly proliferating cells, for treating, inhibiting, or delaying the onset of cancer, and for preventing restenosis in a subject that has undergone an angioplasty or stent: wherein X is selected from the group consisting of alkyl and haloalkyl; Ar is an aryl radical selected from the group consisting of phenyl, biphenyl, naphthyl, anthryl, phenanthryl, and fluorenyl; and wherein Ar is optionally substituted with one or more radicals selected from the group consisting of halo, C 1 -C 4 alkyl, C 1 -C 4 haloalkyl, azido, C 1 -C 4 azidoalkyl, aryl, akylaryl, haloaryl, haloalkylaryl, and combinations thereof; and R is selected from the group consisting of nitrile, acetonitrile, ethylnitrile, propylnitrile, carboxamide, amidine, tetrazole, oxime, hydrazone, acetamidine, aminoacetamide, guanidine, and urea.

  使用一种新型磷脂酰肌醇依赖性激酶-1（PDK-1）抑制剂（化学式I），用于诱导不需要的快速增殖细胞凋亡，治疗、抑制或延缓癌症的发生，并预防在接受血管成形术或支架植入术的患者中再狭窄：其中X选自烷基和卤代烷基的群组；Ar为苯基、联苯基、萘基、蒽基、菲基和芴基中选择的芳基基团；Ar可选地被一个或多个从卤、C1-C4烷基、C1-C4卤代烷基、叠氮基、C1-C4叠氮基烷基、芳基、烷基芳基、卤代芳基、卤代烷基芳基及其组合中选择的基团取代；R选自腈、乙腈、丙腈、羧酰胺、胍、四唑、肟、腙、乙酰胍、氨基乙酰胺、胍、脲中选择的基团。